The World Hypertension Market 2007-2023

The market for hypertensives - led by the angiotensin II antagonists - is one of the largest and most profitable in the global pharmaceutical market, with total anti-hypertensive sales of $36600m in 2006. Hypertension, or high blood pressure, is a worldwide epidemic: by 2025 visiongain predict that worldwide there will be more than 1.5 billion sufferers of this disease. Modern lifestyles, such as poor diet and lack of exercise, are the main contributory factors to elevated blood pressure. Consequently, the incidence and prevalence of hypertension are increasing rapidly in both developed and developing countries.

> In 2005, The Lancet reported that more than 330 million adults in Europe and North America suffer from high blood pressure

> With many more in the developed world the Hypertension market is still relatively untapped

> According to the World Health Organisation, approximately 80% of people with high blood pressure have additional uncontrolled cardiovascular risks

> Hypertension is also strongly age-dependent, with older people being far more susceptible

> Aging populations worldwide therefore constitute a further driver in this prominent market

This is a market you cannot afford to ignore. Are new, potentially successful drugs going to change the market within the next 10 to 15 years? This report will tell you.

The World Hypertension Market 2007-2023 concentrates on the following essential aspects of the market:

> Overview of treatments in the hypertension sector

> Key industrial players in anti-hypertensive treatments

> Forecast of the world anti-hypertensive market from 2007-2023, including forecasts of the leading therapeutic agents

> Forecasts for anti-hypertensive sales in the leading national pharmaceutical markets

> Drivers and opportunities in the anti-hypertensive treatment market

> Restraints and threats in the anti-hypertensive treatment market

> Key opinions from experts in the healthcare sector, academia and medical practice

> Coverage of pipeline developments

The World Hypertension Market 2007-2023 examines the market for antihypertensive drugs critically, through comprehensive primary and secondary research. In addition to consultation with experts in medical practice, academia and industry, this research involved a detailed study of policy documents, industrial reports and relevant news. Importantly, visiongain also applied techniques such as financial forecasting, SWOT analyses and qualitative projections. The result is a comprehensive market-based report with detailed analysis and informed opinion.

Why you should buy this report:

> To receive a comprehensive analysis of the prospects for anti-hypertensive treatments from 2007-2023

> To discover predicted revenues, growth rates and other key metrics for anti-hypertensive treatments from 2006-2023

> To receive the views of experts in the field of hypertension

> To determine the forces that influence the market for anti-hypertensive treatments:

- competitive characteristics of the market

- Drivers

- Restraints

- Strengths, weaknesses, opportunities and threats

> To find out where the hypertension market is heading - both technologically and commercially

The hypertension market is one of the largest in the global pharmaceutical industry, with continued prospects for high revenue generation and market growth. Nevertheless, the hypertension market is facing great challenges in terms of strong internal competition and patent expiration with a concomitant generic threat. Clearly, there are also unmet needs in this market that require urgent attention. While the angiotensin II antagonists have provided an improved balance of efficacy and tolerability in recent years, it is possible that even newer classes of antihypertensive - such as the renin inhibitors - will also provide great therapeutic and commercial scope. Given the great challenges of treating hypertension, continued investment into the development of improved treatments is required, as well as basic scientific research into the disorder. Recent developments in both the pharmaceutical industry and the public sector provide scope for optimism.

Unique benefits to you when you order this report

- Primary research throughout. You will not find this information anywhere else

- Report stored in your reading room for ever

- Full searchable report when you buy the company or corporate editions

- Copies can be printed off for offline reading

- Packed with charts, analysis, figures, graphs and tables

September 2007 PDF Pages 149

Individual report pricing - single user copies of this report are available for only

GBP£1499

USD:3200

Euro:2160

Departmental copies (this entitles up to 5 individual users in your department) of this report are available for only

GBP£2999.

USD:6300

Euro:6300

This is not suitable for library usage

Allow your whole company to have access to this information for only GBP£4999. Company-wide License allows your whole company access and intranet use on CD Rom and .pdf. Suitable for library storage and use.

Does your company have over 2,500 employees? Have the whole company access this information for a special rate of only

GBP£6999

USD:14600

Euro:10093

Table of Contents
Sample Pages

Price
Single User Licence $2995.00
Department Licence 5 Users $5995.00
Company-wide Intranet Licence $9995.00